Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Pancreatobiliary Cancers (AndroMETa-118)

NCT07769502 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07769502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07769502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Pancreatobiliary Cancers (AndroMETa-118)
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
August 17, 2026
Completion date
September 30, 2028
Enrollment
168 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma, pancreatobiliary cancers